DLG4 and Alzheimer disease: Our results showed that the combined treatment of FUS-mediated BBB opening and GAS administration remarkably elevated the level of a neurotrophin (BDNF), a presynaptic marker (SYN), and a postsynaptic marker (PSD-95) in the targeted hippocampus, indicating a BDNF-stimulating effect and better neuroplasticity resulting from the combined intervention, which may be the underlying mechanism of behavioral improvement that AD-like mice presented in the Y-maze.